Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #7076
Reference
MSAN(2020)88
Name
Lithium carbonate (Priadel®) 200mg and 400mg modified release tablets
Categories
Scottish Government
Drug Alerts
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
SCOTLAND
DRUGS
SAFETY
RISKS
PHARMACEUTICAL INDUSTRY
DRUG THERAPY
PHARMACEUTICAL SERVICES
SUPPLIES
Description
1. Priadel® (lithium carbonate) 200mg and 400mg modified-release tablets are being discontinued in the UK and remaining supplies of both strengths are expected to be exhausted by April 2021.
2. Lithium (Priadel®, Camcolit® and Liskonum® brands) is a first line treatment for patients with bipolar disorder. It is also licensed for the treatment and prophylaxis of recurrent depression, and aggressive or self-harming behaviour, and used off-license in the treatment of cluster headaches.
3. Clinical guidance advises that patients must be maintained on the same brand of lithium to ensure that a consistent serum lithium level is maintained. The switching of brands necessitated by the withdrawal of Priadel® will require individualised determination of dose, close monitoring of serum lithium levels and vigilance for relapse and tolerability in all cases.
4. Other brands of lithium carbonate tablets remain available including Liskonum® 450mg modified-release tablets, Camcolit® 400mg modified-release tablets and lithium carbonate Essential Pharma 250mg tablets.
2. Lithium (Priadel®, Camcolit® and Liskonum® brands) is a first line treatment for patients with bipolar disorder. It is also licensed for the treatment and prophylaxis of recurrent depression, and aggressive or self-harming behaviour, and used off-license in the treatment of cluster headaches.
3. Clinical guidance advises that patients must be maintained on the same brand of lithium to ensure that a consistent serum lithium level is maintained. The switching of brands necessitated by the withdrawal of Priadel® will require individualised determination of dose, close monitoring of serum lithium levels and vigilance for relapse and tolerability in all cases.
4. Other brands of lithium carbonate tablets remain available including Liskonum® 450mg modified-release tablets, Camcolit® 400mg modified-release tablets and lithium carbonate Essential Pharma 250mg tablets.
Contact Name
Contact Email
Contact Address
Created
2020-09-03 00:00:00
Click to go back to homepage